PTAC oxalate

Pricing Availability Delivery Time Qty
Cat.No. 4533 - PTAC oxalate | C12H19N3S2.C2H2O4 | CAS No. 201939-40-4
Description: Muscarinic receptor ligand; exhibits partial agonist and antagonist activity at different subtypes
Chemical Name: (1R,5R,6R)-6-[4-(Propylthio)-1,2,5-thiadiazol-3-yl]-1-azabicyclo[3.2.1]octane oxalate
Purity: ≥98% (HPLC)
Datasheet
Citations (1)
Reviews
Literature

Biological Activity

Muscarinic receptor ligand. Displays partial agonist activity at M2 and M4 receptors; exhibits antagonist effects at M1, M3 and M5 receptors (Ki values are 2.8, 0.2, 0.6, 0.2 and 0.8 nM respectively). Displays selectivity for muscarinic receptors over a range of neurotransmitter receptors and ion channels. Inhibits firing rate of dopaminergic cells in the limbic ventral tegmental area after acute administration, without binding to dopamine receptors.

Technical Data

M. Wt 359.46
Formula C12H19N3S2.C2H2O4
Storage Desiccate at RT
Purity ≥98% (HPLC)
CAS Number 201939-40-4
PubChem ID 90488949
InChI Key LXXQOVMTAFXOKQ-IYPAPVHQSA-N
Smiles CCCSC1=NSN=[C@]1[C@@H]2[C@H]3CCCN(C3)C2.O=C(C(O)=O)O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 35.95 100
DMSO 35.95 100

Preparing Stock Solutions

The following data is based on the product molecular weight 359.46. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.78 mL 13.91 mL 27.82 mL
5 mM 0.56 mL 2.78 mL 5.56 mL
10 mM 0.28 mL 1.39 mL 2.78 mL
50 mM 0.06 mL 0.28 mL 0.56 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Safety Datasheet

References

References are publications that support the biological activity of the product.

Raedler et al (2007) Towards a muscarinic hypothesis of schizophrenia. Mol.Psychiatry 12 232 PMID: 17146471

Shannon et al (1999) Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J.Pharmacol.Exp.Ther. 290 901 PMID: 10411607

Bymaster et al (1998) Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. Eur.J.Pharmacol. 356 109 PMID: 9774240


If you know of a relevant reference for PTAC oxalate, please let us know.

Keywords: PTAC oxalate, PTAC oxalate supplier, PTAC, antipsychotics, schizophrenia, selective, muscarinic, partial, agonists, antagonists, M1, M2, M3, M4, M5, Non-selective, Muscarinics, 4533, Tocris Bioscience

1 Citation for PTAC oxalate

Citations are publications that use Tocris products. Selected citations for PTAC oxalate include:

Wang et al (2017) The Analgesic Effects of (5R,6R)6-(3-Propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1] Octane on a Mouse Model of Neuropathic Pain. Anesth Analg 124 1330 PMID: 28002166


Do you know of a great paper that uses PTAC oxalate from Tocris? Please let us know.

Reviews for PTAC oxalate

There are currently no reviews for this product. Be the first to review PTAC oxalate and earn rewards!

Have you used PTAC oxalate?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Alzheimer's

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Cardiovascular

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.